1 Ocak 2019 Dergi makalesi Açık Erişim

Alan, Saadet; Salva, Emine; Yilmaz, Ismet; Turan, Suna Ozbas; Akbuga, Julide

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/68529</identifier>
  <creators>
    <creator>
      <creatorName>Alan, Saadet</creatorName>
      <givenName>Saadet</givenName>
      <familyName>Alan</familyName>
      <affiliation>Inonu Univ, Fac Med, Dept Med Pathol, Malatya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Salva, Emine</creatorName>
      <givenName>Emine</givenName>
      <familyName>Salva</familyName>
      <affiliation>Inonu Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Malatya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yilmaz, Ismet</creatorName>
      <givenName>Ismet</givenName>
      <familyName>Yilmaz</familyName>
      <affiliation>Inonu Univ, Fac Pharm, Dept Pharmacol, Malatya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Turan, Suna Ozbas</creatorName>
      <givenName>Suna Ozbas</givenName>
      <familyName>Turan</familyName>
      <affiliation>Marmara Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Akbuga, Julide</creatorName>
      <givenName>Julide</givenName>
      <familyName>Akbuga</familyName>
      <affiliation>Marmara Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Istanbul, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>The Effectiveness Of Chitosan-Mediated Silencing Of Pdgf-B And Pdgfr-Beta In The Mesangial Proliferative Glomerulonephritis Therapy</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2019</publicationYear>
  <dates>
    <date dateType="Issued">2019-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/68529</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.yexmp.2019.104280</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Platelet-derived growth factor-B (PDGF-B) is a growth factor that plays an important role in the progression of mesangial proliferative glomerulonephritis (MsPGN). PDGF-B may contribute to mesangioproliferative changes and is overexpressed in MsPGN. Recently, small interfering RNAs (siRNAs) have been widely used for gene silencing effects in experimental models of renal diseases. Nanoparticle-based therapeutics are preferred for reasons such as increasing therapeutic efficacy and reducing toxic effects caused by high doses. The distribution of nanoparticles to the kidney is a significant advantage in siRNA delivery. The aim of this study was to investigate the efficacy of chitosan/siRNA nanoplexes in silencing of PDGF-B and PDGFR-beta genes in kidney and to decrease mesangial cell proliferation and matrix accumulation in MsPGN model induced by anti-Thy-1.1 antibody. The therapeutic effects of chitosan/siPDGF-B + siPDGFR-beta nanoplexes in glomerulonephritic rats were studied by molecular, biochemical, and histopathologic evaluations. Chitosan/siPDGF-B + siPDGFR-beta nanoplexes markedly reduced PDGF-B and PDGFR-beta mRNA and protein expressions in experimental MsPGN model. Histopathologic examination results showed that the silencing of PDGF-B and its receptor PDGFR-beta led to reduction in mesangial cell proliferation and matrix accumulation. The use of chitosan/siPDGF-B + siPDGFR-beta nanoplexes for silencing the PDGF-B pathway in MsPGN can be considered as a new effective therapeutic strategy.</description>
  </descriptions>
</resource>